BioCentury | Mar 30, 2015
Clinical News

Firdapse amifampridine regulatory update

...BioMarin (see BioCentury, Nov. 5, 2012). BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Oct 6, 2014
Clinical News

Firdapse amifampridine: Phase III data

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | May 5, 2014
Clinical News

Firdapse amifampridine regulatory update

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Apr 7, 2014
Clinical News

Firdapse amifampridine: Completed Phase III enrollment

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Mar 31, 2014
Clinical News

Firdapse amifampridine: Phase III ongoing

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Feb 10, 2014
Clinical News

Firdapse amifampridine: QT/QTc study data

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Jan 13, 2014
Clinical News

Firdapse amifampridine: Phase III ongoing

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Oct 21, 2013
Clinical News

Firdapse amifampridine: Phase III ongoing

...in the U.S., EU and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Sep 2, 2013
Clinical News

Firdapse amifampridine regulatory update

...Firdapse (see BioCentury, Nov. 5, 2012). BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Apr 1, 2013
Clinical News

Firdapse amifampridine 3: Phase III ongoing

...in the U.S., EU and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
Items per page:
1 - 10 of 18
BioCentury | Mar 30, 2015
Clinical News

Firdapse amifampridine regulatory update

...BioMarin (see BioCentury, Nov. 5, 2012). BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Oct 6, 2014
Clinical News

Firdapse amifampridine: Phase III data

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | May 5, 2014
Clinical News

Firdapse amifampridine regulatory update

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Apr 7, 2014
Clinical News

Firdapse amifampridine: Completed Phase III enrollment

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Mar 31, 2014
Clinical News

Firdapse amifampridine: Phase III ongoing

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Feb 10, 2014
Clinical News

Firdapse amifampridine: QT/QTc study data

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Jan 13, 2014
Clinical News

Firdapse amifampridine: Phase III ongoing

...designation in the U.S. and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Oct 21, 2013
Clinical News

Firdapse amifampridine: Phase III ongoing

...in the U.S., EU and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Sep 2, 2013
Clinical News

Firdapse amifampridine regulatory update

...Firdapse (see BioCentury, Nov. 5, 2012). BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
BioCentury | Apr 1, 2013
Clinical News

Firdapse amifampridine 3: Phase III ongoing

...in the U.S., EU and Switzerland. BioMarin gained the compound through its 2009 acquisition of Huxley Pharmaceuticals Inc....
Items per page:
1 - 10 of 18